Company Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.
The company’s lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.
It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.
The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007.
Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 14, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Les Funtleyder |
Contact Details
Address: 545 Fifth Avenue, Suite 1400 New York, New York 10017 United States | |
| Phone | 212 220 9226 |
| Website | appliedtherapeutics.com |
Stock Details
| Ticker Symbol | APLT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001697532 |
| CUSIP Number | 03828A101 |
| ISIN Number | US03828A1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shoshana Shendelman Ph.D. | Chair of the Board of Directors, Founder, President, Chief Executive Officer and Secretary |
| Les D. Funtleyder | Chief Financial Officer, Principal Financial Officer and Independent Director |
| Dr. Riccardo Perfetti M.D., Ph.D. | Chief Medical Officer |
| Constantine Chinoporos | Chief Operating Officer and Chief Business Officer |
| Catherine Thorpe | Chief Accounting Officer |
| Corwin Dale Hooks | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 6, 2024 | SCHEDULE 13G/A | Filing |
| Dec 2, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |